Search results
16 lut 2023 · A sub-group of patients undergoing IFX infusion developed antibodies to infliximab (ATIs) during progressive infusions, thus becoming non-responders; this condition often leads to treatment failure and the physician’s decision to switch drug.
16 wrz 2019 · Our results demonstrate that Ang II infusion markedly increased the ICAM-1 level in the aorta. Blocking ICAM-1 with a neutralizing antibody significantly attenuated Ang II-induced arterial...
16 lut 2023 · 90K/Mac-2 BP (Mac-2-binding protein), also known as 90K, lectin galactoside-binding soluble 3-binding protein (LGALS3BP) or Galectin-3 binding protein (Gal-3BP), is a N-glycoprotein (PM 70–95 kDa), originally described as a circulating antigen in the supernatant of human breast cancer cells .
16 lut 2023 · In our IBD cohort, high 90K serum levels were found at baseline in patients who then developed anti-infliximab antibodies at the fifth infusion (22 weeks after the first), becoming non-responders (9.76 ± 4.65 µg/mL compared to 6.53 ± 3.29 µg/mL in responder patients, p = 0.005). This difference was significant in the total cohort and in CD ...
10 lut 2022 · Immunohistochemical staining with a Mac-2 antibody revealed that compared with the mice cotreated with saline and IgG control, the mice that received Ang II infusion showed an increased Mac-2-positive area in the aorta and that this increase was dose-dependently reduced in the VCAM-1 antibody-treated mice (Figure 3A).
16 kwi 2020 · Galectin-3 (formerly known as Mac-2), encoded by the LGALS3 gene, is proposed to regulate macrophage adhesion, chemotaxis, and apoptosis. We investigated the role of galectin-3 in determining the inflammatory profile of macrophages and composition of atherosclerotic plaques.
10 lut 2023 · Taken together, we successfully developed a 70K Mac-2bp antibody, 19-8H mAb, using fucosylation screening, and this antibody can be used to elucidate the biological significance of 70K Mac-2bp in cancer biology.
